Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zura Bio Limited (Nasdaq: ZURA) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, multi-asset immunology company developing novel antibodies for autoimmune and inflammatory diseases, Zura Bio uses its SEC filings to report on financial performance, risk factors, governance matters, and material corporate events.
Through periodic reports such as the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Zura Bio presents audited and unaudited financial statements, details on research and development expenses, general and administrative costs, cash and cash equivalents, and net losses. These filings also describe the company’s pipeline, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), and outline key risks associated with its clinical-stage status and lack of approved products.
Current reports on Form 8-K document specific material events, such as leadership transitions, executive appointments, adoption of executive severance plans, financial result announcements, and updates to corporate presentations. For example, Zura Bio has filed 8-Ks regarding changes in its chief executive officer and chief financial officer roles, the launch of investor presentations, and the release of quarterly financial results.
On Stock Titan, these filings are supplemented by AI-powered summaries that aim to explain the main points of lengthy documents, helping readers quickly identify items such as cash runway disclosures, clinical program descriptions, or changes in executive compensation arrangements. Users can also review exhibits referenced in 8-Ks, including press releases and key agreements, where available.
This page is useful for investors and researchers who want to analyze Zura Bio’s official regulatory record, track how its immunology programs are described in formal filings, and monitor governance and compensation developments over time, all with real-time updates sourced from the SEC’s EDGAR system.
Zura Bio Ltd reported that Chief Executive Officer and director Sandeep Chidambar Kulkarni received an employee stock option grant on January 21, 2026. The option covers 2,934,107 Class A Ordinary Shares at an exercise price of $6.32 per share and expires on January 21, 2036.
According to the vesting terms, one fourth of the options will vest on January 21, 2027, and the remaining options will vest in equal quarterly installments, with one twelfth of the remaining shares vesting each quarter. Vesting is conditioned on the CEO’s continuous service with the company.
Zura Bio Limited furnished a new corporate presentation and issued a press release tied to its business outlook. The presentation, dated January 12, 2026, may be used at conferences and investor meetings and is available as Exhibit 99.1 and through the company’s investor website.
The press release, filed as Exhibit 99.2, discusses corporate and clinical trial updates and the company’s outlook for 2026, including its cash runway and expected topline data timelines for two ongoing Phase 2 studies of tibulizumab in hidradenitis suppurativa and systemic sclerosis. Both exhibits are referenced in this current report.
Zura Bio Limited reported that Arnout Ploos van Amstel resigned from its Board of Directors and from the Board’s Nominating and Governance Committee effective December 11, 2025. The company states that his decision is not due to any disagreement with its operations, policies or practices.
The disclosure centers on this board-level governance change. Zura Bio is organized in the Cayman Islands, is an emerging growth company, and its Class A ordinary shares trade on the Nasdaq Stock Market under the symbol ZURA.
Zura Bio Limited reported its Q3 2025 results. Cash and cash equivalents were $139.0 million as of September 30, 2025, compared with $176.5 million at year-end 2024. The company recorded a net loss of $18.0 million for the quarter and $51.5 million for the nine months, reflecting ongoing investment in clinical programs.
Quarterly operating expenses were $19.5 million, with research and development at $11.9 million and general and administrative at $7.6 million. Net cash used in operating activities was $42.5 million for the nine months. Management states it should have sufficient liquidity to fund operations over the next twelve months.
The pipeline centers on Phase 2 development of tibulizumab (ZB-106), a dual IL‑17A/BAFF bispecific antibody. During 2025, the company sold 3,000,000 shares under its ATM at $1.75 for $5.1 million in net proceeds. Class A Ordinary Shares outstanding were 65,018,058 as of September 30, 2025, and 65,023,308 as of November 10, 2025.
Zura Bio Limited furnished a press release announcing its third quarter 2025 financial results. The release was provided as Exhibit 99.1 to a Form 8-K dated November 13, 2025. Under Item 2.02, the information (including Exhibit 99.1) is deemed furnished, not filed, and is not incorporated by reference except as specifically stated.
Zura Bio Limited reported a leadership change triggered by a medical leave. On October 8, 2025, Chief Executive Officer and Board member Robert Lisicki informed the company that he is taking a medical leave of absence effective October 10, 2025.
The Board appointed Kim Davis, currently Chief Operating Officer, Chief Legal Officer and Corporate Secretary, to serve as interim Chief Executive Officer and interim principal executive officer starting October 10, 2025, while she continues in her existing roles. The company notes that there are no special arrangements behind her appointment, no related-party transactions requiring disclosure, and no family relationships between Davis and any directors or executive officers.
Zura Bio Limited reported that its Board adopted an Executive Severance Benefit Plan covering certain employees, including current named executive officers. Under the plan, if an eligible executive is terminated without cause or resigns for good reason after at least 91 days of employment, the Chief Executive Officer may receive a lump sum equal to 12 months of base salary, while other named executive officers and certain executives may receive nine months of base salary.
If a qualifying termination occurs within 12 months after a change in control, the benefits increase. In that case, the Chief Executive Officer may receive 18 months of base salary, 150% of target annual bonus, a prorated bonus for the year of termination based on actual performance, and up to 18 months of COBRA or comparable health coverage reimbursement. Other named executive officers and certain executives may receive 12 months of base salary, 100% of target annual bonus, a prorated actual-performance bonus, and up to 12 months of COBRA or comparable coverage reimbursement.
Zura Bio Limited reported that it has prepared an updated corporate presentation as of September 4, 2025. The presentation may be used at conferences and investor meetings to explain the company’s business and outlook.
The updated deck is filed as Exhibit 99.1 and is also available in the News & Events section of Zura Bio’s investor website. The company notes that this material is being furnished under a disclosure item for investor information and is not considered filed for liability purposes under U.S. securities laws or automatically incorporated into other SEC filings.
Zura Bio Limited filed a current report to furnish a press release dated August 20, 2025. The company states that the information in Item 7.01 and Exhibit 99.1 is being provided under Regulation FD and is considered “furnished,” not “filed,” which means it is not subject to certain liability provisions of the Exchange Act unless later specifically incorporated by reference. The filing identifies the press release as Exhibit 99.1 and also includes a cover page interactive data file as Exhibit 104.
Zura Bio Limited ownership disclosure: A group led by Venrock entities and two individuals reports beneficial ownership of 6,353,353 Class A Ordinary Shares, representing 9.99% of the class as of June 30, 2025. The position reflects direct Class A shares and pre-funded warrants exercisable into additional Class A shares, but those warrants include a Beneficial Ownership Blocker that prevents exercise that would push the group above the 9.99% threshold. The percentage is calculated using 61,874,998 outstanding Class A shares plus 1,722,137 shares issuable on warrant exercise. Voting and dispositive power are shown as shared for the 6,353,353 shares, with no sole voting or dispositive power reported.